1	Altered gene expression and PTSD symptom dimensions in World Trade Center responders
2	
3	Shelby Marchese <sup>1</sup> , Leo Cancelmo <sup>2</sup> , Olivia Diab <sup>2</sup> , Leah Cahn <sup>2</sup> , Cindy Aaronson <sup>2</sup> , Nikolaos P.
4	Daskalakis <sup>2,3</sup> , Jamie Schaffer <sup>2</sup> , Sarah R Horn <sup>2</sup> , Jessica S. Johnson <sup>1</sup> , Clyde Schechter <sup>4</sup> , Frank Desarnaud <sup>2,5</sup> ,
5	Linda M Bierer <sup>2,5</sup> , Iouri Makotkine <sup>2,5</sup> , Janine D Flory <sup>2,5</sup> , Michael Crane <sup>6</sup> , Jacqueline M. Moline <sup>7</sup> , Iris
6	G. Udasin <sup>8</sup> , Denise J. Harrison <sup>9</sup> , Panos Roussos <sup>1,2,10-12</sup> , Dennis S. Charney <sup>2,13,14</sup> , Karestan C Koenen <sup>15-</sup>
7	<sup>17</sup> , Steven M. Southwick <sup>18-19</sup> , Rachel Yehuda <sup>2,5</sup> , Robert H. Pietrzak <sup>18-19</sup> , Laura M. Huckins <sup>1,2,10-</sup>
8	<sup>12,20</sup> *, Adriana Feder <sup>2</sup> * (* equal contribution)
9	
10	<sup>1</sup> Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York,
11	NY 10029, USA
12	<sup>2</sup> Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
13	<sup>3</sup> Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA
14	<sup>4</sup> Department of Family and Social Medicine, Albert Einstein College of Medicine of Yeshiva
15	University, Bronx, NY, USA
16	<sup>5</sup> Department of Psychiatry, James J. Peters Veterans Affairs Medical Center, Bronx, New York, USA
17	<sup>6</sup> Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai,
18	New York, NY, USA
19	<sup>7</sup> Department of Occupational Medicine, Epidemiology and Prevention, Zucker School of Medicine at
20	Hofstra/Northwell, Great Neck, NY, USA
21	<sup>8</sup> Environmental and Occupational Health Sciences Institute, School of Public Health, Rutgers
22	University, Piscataway, NJ, USA
23	<sup>9</sup> Department of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, NYU School of
24	Medicine, New York, NY, USA
25	<sup>10</sup> Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,
26	NY 10029, USA

- 27 <sup>11</sup> Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New
- 28 York, NY 10029, USA
- 29 <sup>12</sup> Mental Illness Research, Education and Clinical Centers, James J. Peters Department of Veterans
- 30 Affairs Medical Center, Bronx, NY 14068, USA
- 31 <sup>13</sup> Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- 32 <sup>14</sup> Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New
- 33 York, USA.
- 34 <sup>15</sup> Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Boston,
- 35 MA, USA.
- 36 <sup>16</sup> Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Cambridge, MA, USA.
- 37 <sup>17</sup> Harvard School of Public Health, Department of Epidemiology, Boston, MA, USA.
- 38 <sup>18</sup> Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
- <sup>19</sup> Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, VA Connecticut
- 40 Healthcare System, West Haven, CT, USA
- 41 <sup>20</sup> Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New
- 42 York, NY 10029, USA
- 43
- 44
- 45
- 46

#### 47 Abstract

48 49 Despite experiencing a significant trauma, only a subset of World Trade Center (WTC) rescue 50 and recovery workers developed posttraumatic stress disorder (PTSD). Identification of 51 biomarkers is critical to the development of targeted interventions for treating disaster responders 52 and potentially preventing the development of PTSD in this population. Analysis of gene 53 expression from these individuals can help in identifying biomarkers of PTSD. 54 55 We established a well-phenotyped sample of 371 WTC responders, recruited from a longitudinal 56 WTC responder cohort, by obtaining blood, self-reported and clinical interview data. Using bulk 57 RNA-sequencing from whole blood, we examined the association between gene expression and 58 WTC-related PTSD symptom severity on (i) highest lifetime Clinician-Administered PTSD 59 Scale (CAPS) score, (ii) past-month CAPS score, and (iii) PTSD symptom dimensions using a 5-60 factor model of re-experiencing, avoidance, emotional numbing, dysphoric arousal and anxious 61 arousal symptoms. We corrected for sex, age, genotype-derived principal components and 62 surrogate variables. Finally, we performed a meta-analysis with existing PTSD studies (total 63 N=1,016), using case/control status as the predictor and correcting for these variables. 64 65 We identified 66 genes significantly associated with highest lifetime CAPS score (FDR-66 corrected p < 0.05), and 31 genes associated with past-month CAPS. Our more granular analyses 67 of PTSD symptom dimensions identified additional genes that did not reach statistical 68 significance in our overall analysis. In particular, we identified 82 genes significantly associated 69 with lifetime anxious arousal symptoms. Several genes significantly associated with multiple

70 PTSD symptom dimensions and lifetime CAPS score (SERPINA1, RPS6KA1, and STAT3) have

71	been previously associated with PTSD. Geneset enrichment of these findings has identified
72	pathways significant in metabolism, immune signaling, other psychiatric disorders, neurological
73	signaling, and cellular structure. Our meta-analysis revealed 10 genes that reached genome-wide
74	significance, all of which were down-regulated in cases compared to controls (CIRBP, TMSB10,
75	FCGRT, CLIC1, RPS6KB2, HNRNPUL1, ALDOA, NACA, ZNF429 and COPE). Additionally,
76	cellular deconvolution highlighted an enrichment in CD4 T cells and eosinophils in responders
77	with PTSD compared to controls.
78	
79	The distinction in significant genes between lifetime CAPS score and the anxious arousal
80	symptom dimension of PTSD highlights a potential biological difference in the mechanism
81	underlying the heterogeneity of the PTSD phenotype. Future studies should be clear about
82	methods used to analyze PTSD status, as phenotypes based on PTSD symptom dimensions may
83	yield different gene sets than combined CAPS score analysis. Potential biomarkers implicated
84	from our meta-analysis may help improve therapeutic target development for PTSD.

#### 85 Introduction

86 Posttraumatic stress disorder (PTSD) is a complex psychiatric disorder that can develop after 87 experiencing a traumatic event. The attacks on the World Trade Center (WTC) on September 11, 88 2001 and their aftermath had a substantial impact on the physical and mental health of WTC 89 rescue, recovery and clean-up workers, but only a subset developed PTSD. These differing clinical outcomes after experiencing trauma imply a role for biological and genetic influence in 90 91 PTSD. Our cohort provides an unprecedented opportunity into PTSD insights, because they have 92 been deeply phenotyped for a shared, specific trauma. 93 Understanding the biological mechanisms underlying PTSD will require careful dissection and 94 95 analysis of many constituent symptoms and risk factors. PTSD is uniquely heterogeneous among 96 psychiatric disorders, with complex and detailed diagnostic criteria that allow for 636,120 different combinations of symptoms<sup>1</sup>, and 79,794 different symptom combinations. Additional 97 98 heterogeneity in PTSD stems from the type and extent of trauma. It has been well established 99 that PTSD is a heterogenous disorder and that trauma type plays a role in differential outcomes. 100 In the field of WTC exposures, some work has already been done to elucidate gene expression and clinical outcomes.<sup>2-10</sup> Further, work by our group and others has demonstrated differential 101 genetic heritability of PTSD according to trauma-type<sup>11,12</sup>. 102 103 104 Identification of biomarkers will be critical to the development of targeted interventions for

treating disaster responders and potentially preventing the development of PTSD in this
population. Gene expression analysis from WTC responders is uniquely useful to deduce the
biological heterogeneity in PTSD, given their exposure to a similar and well-documented trauma.

108 Data on WTC-related traumatic exposures of responders analyzed here, in combination with 109 their heterogenic clinical outcomes, makes this a critical study to understand PTSD development 110 and chronicity after shared traumatic events. Although candidate gene expression and 111 methylation studies have explored genes involved in canonical stress signaling pathways in 112 PTSD, regulated by the hypothalamus-pituitary-adrenal (HPA) axis, and immune and 113 sympathetic nervous systems, few have been able to control for length of time since exposure, 114 nor so specifically delineate trauma type and secondary exposures such as dust cloud severity. 115 While the WTC-related exposures experienced by rescue, recovery and clean-up workers in this 116 cohort ranged in severity, the traumatic event –encompassing the 9/11 attacks and their 117 aftermath– happened in a discrete, specific time window. Further, this sample is highly 118 phenotyped with in-person clinical psychiatric evaluations, also including medical examination 119 and laboratory testing. 120

The existence of this cohort and the generous participation of many responders to the WTC disaster enabled us to generate a large gene expression data set of 355 donors, to our knowledge the largest single traumatic event expression data set to date. We used the Clinician-Administered PTSD Scale (CAPS)<sup>13</sup> score as a quantitative measure of PTSD symptom severity rather than a case/control definition, thus substantially increasing statistical power in this study.<sup>14–16</sup> To our knowledge, ours is the first gene expression study to incorporate total CAPS scores and PTSD symptom dimensions as outcomes.

128

#### 129 Methods

#### 130 **Participants**

131 The WTC Health Program (WTC-HP) is a regional consortium of five clinical centers

- 132 established in the greater New York City area by the Centers of Disease Control and Prevention
- in 2002, with the goal of providing health monitoring and treatment to WTC responders,

134 comprising the WTC-HP General Responder Cohort<sup>17</sup>. We recruited participants from the WTC-

135 HP Responder Cohort who had completed at least three periodic health monitoring visits at one

136 of the four WTC-HP clinical centers participating in this study – Mount Sinai Medical Center,

137 New York University, Northwell Health, and Rutgers/The State University of New Jersey – and

138 who had provided signed consent to be contacted for research studies. Stratified random

139 sampling was employed to ensure selection of WTC responders spanning the full range of WTC-

140 related PTSD symptom severity, from no/minimal symptoms to severe/chronic PTSD symptom

141 levels on the PTSD Checklist – Specific Version (PCL-S)<sup>18</sup> completed during periodic health

142 monitoring visits to the WTC-HP. Individuals with a lifetime history of chronic psychotic

143 disorder or bipolar disorder type I, substance abuse/dependence or alcohol dependence over the

144 prior three months, current pregnancy, acute medical illness or exacerbation of chronic medical

illness, history of significant head injury or cerebrovascular accident, changes in medications or

medication dosages over the prior month, or who were taking oral or regularly injected steroidmedications were excluded from the study.

148

149 The study, conducted between April 2013 and September 2017, was approved by the

150 Institutional Review Board of the Icahn School of Medicine at Mount Sinai, and all participants

151 provided written informed consent. A total of 471 WTC responders completed in-person clinical

152	assessments, yielding a final sample of 371 participants who met study eligibility criteria and
153	completed study procedures, and 355 of those who had viable RNA-sequencing data (Figure 1).
154	The mean age of participants was 54.1 (SD=8.3) years, 82% were male; ethnicity proportions are
155	given in Table 1. The sample was composed of 40.8% police responders and 59.2% non-
156	traditional responders (e.g., construction workers).
157	
158	Assessments
159	Data on 10 WTC-related exposures <sup>19</sup> (e.g., exposed to human remains, received treatment for an
160	illness/injury during WTC recovery work) was obtained from interviews and self-report
161	questionnaires completed by participants during their first health-monitoring visit to the WTC-
162	HP, an average of 4.3 (SD=2.7) years following 9/11/2001. In-person clinical assessments were
163	conducted an average of 13 (SD=2.3) years following 9/11/2011. Trained Masters- or PhD-level
164	clinical interviewers administered the Structured Clinical Interview for DSM-IV (SCID) <sup>1</sup> to
165	assess current and lifetime Axis-I psychiatric diagnoses, and CAPS <sup>13</sup> , lifetime and past-month
166	versions, to assess lifetime and past-month WTC-related PTSD diagnostic status and WTC-
167	related PTSD symptom severity. Lifetime and past-month PTSD diagnosis was defined as
168	meeting DSM-IV criteria for WTC-related PTSD and a total score $\geq 40$ on the lifetime and past-
169	month CAPS, respectively.
170	
171	On the same day as the clinical assessment, participants also completed the Childhood Trauma
172	Questionnaire $(CTQ)^{20}$ , assessing physical, sexual, and emotional abuse, and physical and

172

emotional neglect experienced in childhood; the Traumatic Life Events Questionnaire (TLEQ)<sup>21</sup>, 173

assessing lifetime exposure to a range of traumatic events (e.g, crime, natural disaster, assault); a 174

175 checklist of 15 stressful life events they might have experienced since 9/11/2011 (e.g., "lost a job/laid off/lost income", "divorced from spouse", "had debt trouble"), modified from the 176 Diagnostic Interview Schedule (DIS) Disaster Supplement<sup>22</sup>; and a health questionnaire asking 177 which medical conditions they had ever been diagnosed with<sup>23</sup>, modified to add common WTC-178 179 related conditions (asthma or chronic respiratory condition, chronic rhinitis or sinusitis, sleep 180 apnea, or acid reflux). Participants additionally completed a history and physical examination 181 conducted by a licensed nurse practitioner, as well as routine laboratory testing, to rule out acute 182 medical illness or exacerbation of chronic medical illness. 183 Among the 355 participants, 108 were determined to have met DSM-IV criteria for lifetime 184 185 WTC-related PTSD, with 53 of them still meeting past-month PTSD criteria. The heterogeneity 186 of PTSD confers some problems when attempting to analyze the disorder by case/control status 187 alone. Case/control analyses do not fully capture the symptom complexity of the disorder, 188 resulting in poor genomic modeling. Similarly, while overall PTSD symptom severity is a better 189 quantitative measurement, it does not fully capture variability across PTSD symptomatology on a useful clinical level.<sup>24</sup> To address this variability, we examined five symptom dimensions (re-190 191 experiencing, avoidance, emotional numbing, dysphoric arousal and anxious arousal symptoms), 192 assessed with the CAPS to more accurately examine the heterogeneity of PTSD symptomatology (Figure 2). $^{25}$ 193

194

### **Blood sample collection and RNA extraction**

196 Participants were instructed to fast after midnight and underwent collection of blood samples197 between 8:00 and 10:00 am. Total RNA was purified from whole blood collected in PAXgene

198 blood RNA tubes (Qiagen, Germantown, MD, USA) using a PAXgene blood RNA kit IVD 199 (Qiagen, Germantown, MD, USA). Total RNA concentration and quality were estimated using a 200 NanoDrop 200c spectrophotometer according to the manufacturer instructions (Thermo Fisher 201 Scientific, Waltham, MA, USA). Samples with an optical density ratio 260/280 superior or equal 202 to 1.8 passed the quality control. Total RNA concentration and quality were also estimated using 203 an Agilent RNA 6000 nano kit and an Agilent 2100 bioanalyzer according to the manufacturer 204 instructions (Agilent Technologies, Santa Clara, CA, USA). Samples with an RNA Integrity 205 Number superior or equal to 7 passed the quality control. RNA samples (derived from blood) 206 were processed for RNA Seq with polyA selection and sequenced on Illumina HiSeq High 207 Output mode with a sequencing configuration of 2x150 paired-end reads (GENEWIZ, South 208 Plainfield, NJ). A total of 10M paired reads per sample was set as a threshold to account for high 209 globin reads; 29 samples were re-sequenced to meet threshold.

210

#### 211 Gene expression quality control analysis

212 We processed whole-blood gene expression data using the RAPiD.19 RNA-sequencing pipeline, and calculated normalized TPM counts from RSEM.<sup>26</sup> We performed quality control analysis on 213 the counts to verify sequencing and residual contributions to variance using VariancePartition<sup>27</sup>. 214 215 We corrected each sequencing batch for sex, age, and genotype-derived principal components using Limma/voom weighted least-squares linear regression.<sup>28</sup> We rank normalized and 216 217 combined the residuals from the linear regression of each batch, and these values were used in all 218 subsequent association tests for CAPS total score and five PTSD dimension scores (re-219 experiencing, avoidance, numbing, dysphoric arousal and anxious arousal).

220

# 221 **Differential gene expression analysis** 222 We used whole blood RNA-sequencing to test for associations between gene expression and 223 WTC-related PTSD symptom severity on (i) highest lifetime CAPS score (CAPS<sub>L</sub>), (ii) past-224 month CAPS score (CAPS<sub>PM</sub>), and (iii) PTSD dimension scores including re-experiencing, 225 avoidance, numbing, dysphoric arousal and anxious arousal, correcting for batch and surrogate 226 variables (Eqn. 1). 227 Gene expression $\sim Dx + batch + surrogate$ variables 228 229 Equation 1. General equation for gene expression analysis. 230 231 In addition, study participants had a wide range of psychiatric and somatic comorbidities, 232 including some with substantial shared genetic aetiology and overlapping symptom profiles (e.g., 233 major depressive disorder); comorbidities that may represent systemic manifestations of of PTSD (e.g., cardiovascular disease<sup>29</sup>); and exposure to the dust cloud during and following 9/11. 234 235 We expect all of these factors to have substantial impacts on gene expression. Significant co-236 linearity between some of these measures and CAPS scores preclude including these variables as 237 covariates within our analysis, and testing directly for their effect on gene expression (in 238 particular, due to high correlations between length of time at the WTC site, CAPS score, and 239 dust-cloud exposure [ref]; and between CAPS score and co-morbid medical disorders potentially 240 constituting systemic manifestations of PTSD). Instead, in order to test whether these 241 comorbidities and exposures might account for some of the CAPS-expression associations we

242 observe, we also tested for gene expression associations with (i) an index of dust cloud

exposure<sup>30</sup>; and (ii) number of medical comorbidities. Next, we tested for (i) interaction effects
between each of these measures and CAPS score; (ii) enrichment of genome-wide significant
associations between these measures and CAPS score; and (iii) genome-wide correlations in
association statistics. For all gene expression analyses, we established significance using a
Benjamini-Hochberg<sup>31</sup> FDR correction < 5%.</li>

248

# 249 Gene-set enrichment of PTSD-associated genes

We tested for gene set enrichment among our genes associated with  $CAPS_L$ ,  $CAPS_{PM}$ , and PTSD dimension scores by (i) analyzing the significant genes from the association tests for pathway enrichment by gene permutation testing and (ii) analyzing all genes from the ranked association test gene lists to subject permutation using the R versions of GSEA<sup>32</sup> and fgsea<sup>33,34</sup>. For gene permutation testing, we included all nominally significant genes (p<0.05), and tested for association with 105 gene sets using Kyoto Encyclopedia of Genes and Genomes (KEGG) database<sup>35</sup> for pathway enrichment.

257

We applied phenotype permutation testing rather than gene set permutation to keep the
correlations between the genes in the dataset and the genes in the gene set pathways. For the
subject permutation testing, each test was run with 10000 permutations, and pathways that
passed Benjamini-Hochberg multiple testing correction were considered significantly enriched.
To synthesize this large amount of gene set information, we generated comparative PTSD
symptom plots using Clusterprofiler<sup>36</sup> in R. Comparative gene set plots contained pathways
which passed FDR<0.05 significance threshold.</li>

265

#### 266 Meta-analysis with existing gene expression analyses

- 267 To replicate our gene expression results, we meta-analyzed our data with association statistics
- 268 from five other genome-wide gene expression analyses:
- 269 1. WTC responder study Stony Brook University (SB WTC)<sup>3</sup>; N=282. Data are divided
- 270 into discovery (WTC-d) and replication (WTC-r) cohorts.
- 271 2. Trauma Mega-Analysis study (TMA)<sup>12</sup>. TMA combines 7 different PTSD studies and
- transformed the expression data into three categories: combat (N=169), male
- interpersonal (N=112), and female interpersonal trauma (N=259)<sup>12</sup>. We analyzed these
- data as separate trauma studies for the purposes of our meta-analysis (Table 2).

275

276 Since the majority of studies focus on PTSD case/control status, rather than associations with

277 continuous CAPS scores (as here), we repeated our analysis to compare gene expression between

278 PTSD cases (defined as meeting DSM-IV criteria for PTSD and a total CAPS  $\geq$  40) and controls

279 (all others in our sample).

280

281 We meta-analyzed PTSD case-control association statistics using a sample-size based meta-

analysis approach in METAL<sup>37</sup>. We included all genes from our analysis that reached p<0.05

(N=9,380 for past-month and N=1,016 for lifetime) and all available genes from other studies
(N=27-806; Table 2).

#### 285 Cellular deconvolution associated with CAPS scores

286

287 We applied CIBERSORT to our raw counts matrix to deconvolute immune cell types in our

patients using the immune cell matrix reference panel  $LM22^{38}$ . We tested for association

289 between cell type proportions and  $CAPS_{PM}$ ,  $CAPS_{L}$ .

# 290 Results

#### 291 Gene expression is associated with PTSD symptom levels in WTC first responders

- 292 We tested for association between expression of 12,220 genes and total CAPS score in a sample
- 293 of 355 WTC first responders. We identified 31 genes significantly associated with total past-
- 294 month CAPS score (CAPS<sub>PM</sub>; Figure 3), and 66 genes associated with lifetime (highest) CAPS
- score (CAPS<sub>L</sub>, Figure 3). Of these, 42/66 genes are associated only with CAPS<sub>L</sub>, (and not
- 296 CAPS<sub>PM</sub>), while 7/31 genes were associated only with CAPS<sub>PM</sub>, (and not CAPS<sub>L</sub>). Genome-wide
- associations with CAPS<sub>PM</sub> and CAPS<sub>L</sub> were significantly correlated (Beta  $\rho = 0.82$ , p<2.2x10<sup>-16</sup>;
- 298 FDR-adjusted P-values  $\rho = 0.79$ , p<2.2x10<sup>-16</sup>) (Table 3).
- 299

300 We tested for enrichment of 59 well-studied PTSD candidate genes<sup>11</sup> (Sup. Table 1) within our

301 association statistics. We did not observe enrichment of these genes within our past-month or

302 lifetime association analyses (p=0.174, 0.245). However, of these candidate genes, SERPINA1

- 303 was significantly associated with  $CAPS_L$  score.
- 304

### 305 Environmental exposure to the WTC dust cloud

Next, we tested whether our genes associated with CAPS scores are specific to PTSD, or are driven by spurious associations with comorbid diagnoses or environmental exposure to the dust cloud at Ground Zero. In particular, a number of individuals within our study have comorbid conditions and complex medical histories (Table 4), including disorders with substantial shared genetic and environmental etiology with PTSD, and disorders and traits that may present as systemic manifestations of PTSD.

312

313	First, we tested whether these medical comorbidities alone may account for the associations we
314	observe; we identified 175 gene associations with an aggregate summary score of medical
315	comorbidities. Notably, these genes do not include any of our significant associations with CAPS
316	scores. We identified only one gene, STX10, with significant interaction between CAPS scores
317	and comorbid conditions; that is, gene expression was elevated specifically among individuals
318	with both high $CAPS_L$ and a large number of comorbid diagnoses (Figure 4).
319	
320	Next, we tested for association between gene expression and exposure to the dust cloud at
321	Ground Zero <sup>30</sup> . We identified 561 genes significantly associated with this exposure. We tested
322	for, but did not find, any significant interactions between CAPS scores and dust cloud exposure
323	(p>0.05), and did not observe a large correlation of expression results in genome-wide
324	significant genes between the two analyses for $CAPS_{PM}$ or $CAPS_{L}$ (R <sup>2</sup> =0.1835, R <sup>2</sup> =0.2466,
325	p<0.05) (Figure 4). Together, these analyses imply that our gene-CAPS score associations are
326	specific and relevant to PTSD, rather than due to confounding by comorbid diagnoses or dust
327	cloud exposure.
328	
329	Gene expression analysis reveals PTSD dimension-specific associations
330	Next, we tested for gene expression associations with past-month and lifetime PTSD symptom
331	dimensions (re-experiencing, avoidance, dysphoric arousal, anxious arousal, numbing; Table 5).
332	Our analysis revealed overlapping and unique genes for each symptom dimension, and
333	significant correlation of genome-wide association statistics between symptom dimensions.
334	In particular, both our past-month and lifetime analyses identified a large number of genes (61
335	and 82, respectively; Table 5) associated with anxious arousal, including many genes not

associated with any other phenotype in our analysis (16, 27, respectively). By contrast, although
we identified a substantial number of genes significantly associated with dysphoric arousal (20,
16 for past-month and lifetime respectively), only two genes were uniquely associated with this
phenotype (1 gene in past-month; 2 in lifetime). Only one gene, *COPE*, was significantly
associated with every phenotype tested in our analysis. A second gene, *EIF4A1*, was also
significantly associated with every lifetime (highest) phenotype (Figure 5).

342

# 343 **PTSD** pathway enrichment demonstrates immune, psychiatric, and metabolic relationships

344 Our genetic enrichment and pathway analyses identified well-established PTSD mechanisms and

345 pathways, including pathways associated with inflammation, neurological signaling pathways,

structural remodeling within and between cells, and HPA-axis and signaling  $^{39-44}$ . Based on our

347 KEGG pathway enrichment analysis, we revealed a set of genes significantly associated with

348 psychiatric disorders pathways that were significantly enriched in our results: *FURIN*, *PPP2R1A*,

349 GNAI2, PCLB2, and GNB2. The two symptoms that we discovered were associated with FURIN

and their FDR-corrected p-values were avoidance (p=0.028, B=2.55) and numbing (p=0.034,

B=-0.009). *PPP2R1A* was associated with anxious arousal (p=0.009, B=2.60). *PCLB2* was only

associated with numbing (p=0.046, B=-0.952). *GNAI2* was associated with anxious arousal

(p=0.042, B=-0.780) and numbing (p=0.047, B=-1.03), and *GNB2* was only associated with

avoidance (p=0.036, B=1.130) (Figure 6).

355

Immunological and metabolic gene enrichment was consistent across  $CAPS_L$  score and numbing, but was less pronounced in anxious arousal. For past-month analyses, immune function was most associated with anxious arousal, whereas metabolic function was enriched in  $CAPS_{PM}$  and

359	numbing, to a lesser extent. For both lifetime and past-month scores, neurological signaling
360	pathways were most significantly pronounced in numbing, and were less prevalent in the overall
361	total CAPS score analysis. For lifetime scores, structural pathway enrichment was significantly
362	higher in total CAPS score, anxious arousal, and numbing, whereas for past-month scores,
363	structural enrichment was most associated with anxious arousal (Figure 6).
364	
365	Meta-analysis prioritizes 10 genes associated with PTSD
366	We sought to replicate our associations with previous PTSD studies. Since the majority of
367	publicly available PTSD gene expression analyses follow a case-control, rather than quantitative
368	measure (CAPS score) analysis, we converted our continuous $\text{CAPS}_{\text{PM}}$ and $\text{CAPS}_{\text{L}}$ values to
369	PTSD case/control using (CAPS≥ 40) and DSM-IV PTSD-criteria, and repeated our analysis.
370	Our case/control and CAPS score association statistics were significantly correlated ( $\rho$ =0.72,
371	$p < 2.2 \times 10^{-16}$ , $\rho = 0.79$ , $p < 2.2 \times 10^{-16}$ ); however, we note a substantial decrease in the number of
372	significantly associated genes when using a case-control design, compared to our initial
373	quantitative analysis, as we would expect <sup>16</sup> . Twelve genes were significant for past-month PTSD
374	(PTSD <sub>PM</sub> ) case/control and 22 genes were significant for lifetime PTSD (PTSD <sub>L</sub> ) case/control,
375	versus 31 genes for $CAPS_{PM}$ and 66 genes for $CAPS_{L}$ .
376	

We meta-analyzed our results with five publicly available cohorts (N=739 cases, 438 controls);

two including WTC responders, and three including combat and interpersonal trauma (Table 2).

379 For PTSD<sub>PM</sub> we identified 5 significant genes –*COPE*, *CIRBP*, *FCGRT*, *NACA*, and *ZNF429* 

380 (p< $5.33 \times 10^{-6}$ )-, and for PTSD<sub>L</sub> 8 significant genes –*COPE*, *CIRBP*, *TMSB10*, *FCGRT*, *CLIC1*,

381 *RPS6KB2, HNRNPUL1* and *ALDOA* ( $p < 4.92 \times 10^{-5}$ )–, including genes associated with

382 inflammation and immune response (Figure 7). Of these 10 genes, only one (COPE) had 383 significant heterogeneity of effect size between cohorts: our study and TMA-combat. Three further genes were unique to our study; NACA  $p=3.34 \times 10^{-6}$ , CLIC1,  $p=1.9 \times 10^{-5}$ , and HNRNPUL1 384  $p=4.08 \times 10^{-5}$  (Figure 7). The remaining six genes were significant across multiple studies in our 385 386 meta-analysis, with highly consistent (negative) direction of effect (i.e., consistently decreased expression in cases compared to controls): ZNF439 (p=4.78x10<sup>-6</sup>), CIRBP (p=1.29 x10<sup>-6</sup>), 387 *TMSB10* (p=6.31 x10<sup>-6</sup>), *FCGRT* (p=1.12 x10<sup>-5</sup>), *RPS6KB2* (p=3.47 x10<sup>-5</sup>), and *ALDOA* (p=4.66) 388 389  $x10^{-5}$ ) (Table 6). 390 391 Cellular deconvolution identifies differences in cell populations between responders with 392 **PTSD and controls** 393 Since many of our PTSD-associated genes are related to immune function, we tested whether 394 immune cell type proportions were correlated with CAPS scores in individuals in our sample. 395 We performed cell-type deconvolution to identify cell-type proportions for 22 cell types across 396 all 355 individuals in our sample. We found significant increase of CD4 naïve T cell (p<0.0049) 397 proportions with CAPS<sub>PM</sub>, and significant increase of eosinophils (p < 0.042) and CD4 memory 398 resting T cells (p<0.044) associated with CAPS<sub>L</sub>. In addition, we found significant decrease of 399 activated natural killer cells (p<0.040) associated with CAPS<sub>L</sub> (Figure 8). 400

#### 401 Discussion

402 Although trauma is ubiquitous as a human experience, the types of traumatic experiences vary 403 greatly among individuals. Our study sample and design present a unique opportunity to examine 404 gene expression and PTSD symptoms related to a particular traumatic experience, the 9/11 WTC 405 disaster and its aftermath. To our knowledge, ours is the largest single-traumatic event gene 406 expression dataset to date. Using CAPS score as a quantitative measure of WTC-related PTSD 407 symptom severity, we found 66 genes associated with lifetime (highest) CAPS score and 31 408 genes associated with past-month CAPS score. We additionally found interaction between 409 CAPS<sub>L</sub> and one gene, STX10, in medical comorbidities. Pathway analysis links our associated 410 genes to metabolic, immunological, structural, and neurological pathways. In addition, we found 411 10 genes associated with lifetime and past-month PTSD: COPE, CIRBP, and FCGRT shared 412 between the two; NACA and ZNF429 specific to past-month PTSD; and TMSB10, CLIC1, 413 RPS6KB2, HNRNPUL1 and ALDOA specific to lifetime PTSD. Furthermore, cellular analysis of 414 our cohort demonstrated an enrichment in CD4 T cells and eosinophils in responders with PTSD. 415 Additionally, natural killer cells were decreased in these patients. Our findings support previous 416 studies which tie together the immune system and PTSD as a systemic disease. Ultimately, these 417 results represent an additional wealth of knowledge to help understand the genetic expression 418 and biological etiology of PTSD and uncover potential biomarkers for the disease. 419

Examining both lifetime and past-month CAPS scores allowed us to look at not only chronic
effects of PTSD but longevity of the outcomes. While CAPS<sub>PM</sub> is considered the standard for
case/control analysis, looking at both CAPS<sub>L</sub> and CAPS<sub>PM</sub> allows us to ask more specific
questions about the role and relevance of elevated gene expression in PTSD. For example, genes

424 associated with  $CAPS_{PM}$  might represent current expression changes in PTSD, while those 425 associated with CAPS<sub>1</sub> (lifetime CAPS score representing, for each responder, the highest WTC-426 related PTSD symptom levels ever reached since 9/11/2011) may represent long-lasting 427 expression changes resulting from lifetime PTSD. 428 429 We identified genes associated with past-month and lifetime CAPS scores that have been 430 associated with other psychiatric disorders, such as major depressive disorder, schizophrenia and autism: FURIN, PPP2R1A, PLCB2, GNAI2, and GNB2 (Figure 6)<sup>45-57</sup>. We additionally 431 identified a group of genes as significantly associated with several lifetime and past-month 432 433 PTSD symptom dimensions (SERPINA1, RPS6KA1, and STAT3) that have been previously linked to PTSD pathophysiology<sup>1,27-31</sup>, and genes associated specifically with anxious arousal 434 that have been previously associated with anxiety disorders: *DCTN1*, and *FLI1*<sup>58,59</sup>. One gene in 435 436 our study, COPE, was associated with every PTSD phenotype in this analysis. Until now, COPE has not been well studied in the context of psychiatric disorders<sup>60</sup>, but it has been implicated in 437 the context of Alzheimer's disease $^{61,62}$ . Canonically, the COPE protein is the epsilon subunit of 438 439 the coatomer protein complex I (COPI) which regulates endocytosis from the plasma membrane 440 and is involved in Golgi-to-lysosome transportation. Other subunits of COPI have been implicated in hereditary diseases that cause microcephaly and in autoimmune disorders<sup>63–65</sup>. 441 442 Importantly, our analytical design allowed us to test for potential confounding effects of 443

444 comorbidities and environmental exposures<sup>66,67</sup>. We expected many of these comorbidities and 445 exposures to have a significant impact on gene expression, particularly as some comorbidities 446 may be more recently occurring than, for example, the highest CAPS<sub>L</sub> measure. Therefore, we

447	tested directly for genes associated with (i) comorbidities and (ii) dust cloud exposure. Although
448	we identified a large number of genes associated with each phenotype, we note that our
449	associations do not overlap with our top PTSD genes; we did not observe significant enrichment
450	of shared associations, and only observed one gene with significant interaction effect between
451	comorbidities and $CAPS_L$ . Therefore, we conclude that our results are not confounded by these
452	exposures; our gene associations are specific to PTSD rather than broadly corresponding to
453	exposure or general ill-health.
454	
455	KEGG enrichment of our associated genes determined genetic changes in metabolic,
456	immunological, structural, and neurological pathways associated with total CAPS, numbing, and
457	anxious arousal phenotypes (Figure 7). Anxious arousal and numbing tend to have few
458	significantly associated genes in common, while both past-month and lifetime CAPS scores
459	display a few unique genes but many shared ones. GNAI2, while associated with many numbing-
460	related pathways (long-term depression, oxytocin signaling, etc.), is also significantly associated
461	with some peripheral anxious arousal-related and CAPS <sub>L</sub> -related pathways (leukocyte migration,
462	and chemokine signaling, respectively). On the other hand, anxious arousal is uniquely
463	associated with genes such as HGS, ARFGAP2 and RAB7A, which are linked to endocytosis and
464	immunity. Similarly, our past-month and lifetime CAPS phenotypes are uniquely associated with
465	glycolysis/gluconeogenesis for genes ALDOA, GAPDH, ENO1, TPI1, and PKM, which may play
466	roles in HPA-axis or metabolic dysregulation (Table 4).
467	
468	Our analyses identified 10 genes reaching genome-wide significance. Of these, 3/10 (NACA

469  $p=3.34 \times 10^{-6}$ , *CLIC1*,  $p=1.9 \times 10^{-5}$ , and *HNRNPUL1*  $p=4.08 \times 10^{-5}$ ) are specific to our study; all

470 three are downregulated in WTC responders with PTSD compared to controls. NACA has been previously studied as a potential biomarker for depression in mice under stress conditions<sup>68</sup>. The 471 function of *HNRNPUL1* is relatively unknown. Studies have suggested it might play a role in 472 473 DNA damage repair and nucleocytoplasmic RNA transport. CLIC1 has been implicated in other psychiatric disorders, but its primary function is inflammasome regulation  $^{69-71}$ . In addition, 6/10474 genes had highly consistent directions of effect. These include FCGRT (p=1.12x<sup>-05</sup>), which has 475 476 been characterized as an immune regulator of dendritic cell cross-presentation of IgG immune complexes, necessary to activate a cytotoxic T-cell response and clear antigens<sup>72</sup>. Our analysis 477 demonstrates a down-regulation of FCGRT in WTC responders with PTSD, suggesting reduced 478 479 IgG immune complex clearance in these patients (Figure 6). 480 481 There is evidence that macro- and micro-level physiological damage is a fundamental component 482 of PTSD, as well as cytoskeletal restructuring for fear-based memory formation in the amygdala<sup>43,44</sup>. In this study we observed decreased expression in *CIRBP* ( $p=1.29x^{-06}$ ), a protein 483 484 that traditionally regulates stress and apoptosis under conditions of extreme cold (Figure 6). Its role as a potential biomarker has been previously explored for different psychiatric disorders<sup>73,74</sup>. 485 486 The decrease observed in TMSB10 expression also contributes to the dysregulation of apoptosis. 487 TMSB10 is a pro-apoptotic protein that has been previously associated with downregulation of gene expression after trauma exposure  $^{3,75,76}$ . In our meta-analysis, the directionality of effect 488  $(p<2.2x^{-16})$  for each gene was decreased, consistent with PTSD pathophysiology<sup>77,78</sup>. 489 490

491 Since many of our PTSD-associated genes are related to immune function, we tested for the

492 enrichment of immune cell types in our study. We found an overall enrichment of CD4-positive

493 T cells for both past-month and lifetime CAPS scores (Figure 7), consistent with previous studies<sup>79,80</sup>, including among WTC responders<sup>8</sup>. In addition to CD4 T cell enrichment, our study 494 495 also found enrichment in eosinophils and a decrease in natural killer cells for CAPS<sub>L</sub> (Figure 7). 496 These cellular diversities may point to a higher inflammatory signature in PTSD, particularly in 497 the case of CD4 T cell enrichment. It has been well demonstrated that dysregulation of CD4 T cells leads to autoimmune activation<sup>81</sup>, and in combination with an increase in eosinophils can 498 499 lead to an inflammatory cascade in patients. There is strong evidence that PTSD is associated with a pro-inflammatory state, which our findings  $support^{82-86}$ . 500

501

502 While our study provides an in-depth look at the genetic expression and outcomes related to a 503 specific traumatic experience, we note some significant caveats. Our expression analysis was 504 limited to blood, but should be expanded to other tissues in the future, such as the brain. 505 Similarly, our analysis was restricted to whole blood, but a more in-depth single cell analysis 506 will be critical to determine gene expression in individual cell types. In addition, we note that our 507 cohort includes a significant proportion of individuals who have self-selected into high-risk 508 professions. As such, we expect a higher lifetime exposure to stressful situations, including 509 potentially many other life-threatening scenarios. It is likely that the PTSD symptoms observed 510 here are at least partially accounted for by other traumas and stressors, even though upon CAPS 511 administration, study clinicians specifically inquired about WTC-related PTSD symptoms. 512 Conversely, the high-risk nature of these individuals' occupations may also mean increased 513 exposure to resilience training for a sizable subsample, and greater access to social support 514 networks of peers with similar experiences, potentially providing protective mechanisms.

515

- 516 In conclusion, this study has identified a vast number of biomarkers that will be potentially
- 517 useful tools after independent validation. In particular, ten of these genes stand out as
- reproducible across multiple studies and should be considered as high priority. In combination
- 519 with pathway and cellular deconvolution results, these findings highlight a strong connection
- 520 with immune dysregulation and other psychiatric illnesses. We believe that future studies should
- 521 focus on validation of our PTSD-associated genes and also single-cell RNA-sequencing
- 522 approaches to delineate the role of immune cell types in PTSD.

# 523 **References**

- 1. Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I
- 525 Disorders (SCID). N. Y. State Psychiatr. Inst. Biom. Res. N. Y. (1995).
- 526 2. Yehuda, R. et al. Gene Expression Patterns Associated with Posttraumatic Stress Disorder
- 527 Following Exposure to the World Trade Center Attacks. *Biol. Psychiatry* **66**, 708–711 (2009).
- 528 3. Kuan, P.-F. *et al.* Gene expression associated with PTSD in World Trade Center responders:
- 529 An RNA sequencing study. *Transl. Psychiatry* **7**, 1297 (2017).
- 530 4. Clouston, S. *et al.* Traumatic exposures, posttraumatic stress disorder, and cognitive
- 531 functioning in World Trade Center responders. *Alzheimers Dement. N. Y. N* **3**, 593–602
- 532 (2017).
- 533 5. Clouston, S. A. P. et al. Posttraumatic stress disorder and total amyloid burden and amyloid-
- 534  $\beta$  42/40 ratios in plasma: Results from a pilot study of World Trade Center responders.
- 535 *Alzheimers Dement. Amst. Neth.* **11**, 216–220 (2019).
- 536 6. Clouston, S. A. P. *et al.* Incidence of mild cognitive impairment in World Trade Center
- responders: Long-term consequences of re-experiencing the events on 9/11/2001.
- 538 Alzheimers Dement. Diagn. Assess. Dis. Monit. **11**, 628–636 (2019).
- 539 7. Gong, Y. *et al.* Prostate Cancer in World Trade Center Responders Demonstrates Evidence
- of an Inflammatory Cascade. *Mol. Cancer Res.* **17**, 1605–1612 (2019).
- 541 8. Kuan, P.-F. et al. Cell type-specific gene expression patterns associated with posttraumatic
- 542 stress disorder in World Trade Center responders. *Transl. Psychiatry* **9**, 1–11 (2019).
- 543 9. Kuan, P.-F. *et al.* Enhanced exposure assessment and genome-wide DNA methylation in
- 544 World Trade Center disaster responders. *Eur. J. Cancer Prev.* **28**, 225–233 (2019).

- 545 10. Sarapas, C. *et al.* Genetic Markers for PTSD Risk and Resilience Among Survivors of the
- 546 World Trade Center Attacks. *Dis. Markers* **30**, 101–110 (2011).
- 547 11. Huckins, L. M. *et al.* Analysis of Genetically Regulated Gene Expression identifies a trauma
- 548 type specific PTSD gene, SNRNP35. *bioRxiv* 581124 (2019) doi:10.1101/581124.
- 549 12. Breen, M. S. *et al.* PTSD Blood Transcriptome Mega-Analysis: Shared Inflammatory
- 550 Pathways across Biological Sex and Modes of Trauma. *Neuropsychopharmacology* **43**, 469–
- 551
   481 (2018).
- 13. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD
- 553 Scale. J Trauma Stress 8(1), 75–90 (1995).
- 554 14. Fanous, A. H. & Kendler, K. S. Genetic heterogeneity, modifier genes, and quantitative
- phenotypes in psychiatric illness: searching for a framework. *Mol. Psychiatry* 10, 6–13
  (2005).
- 557 15. Schijven, D. et al. Multivariate genome-wide analysis of stress-related quantitative
- 558 phenotypes. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 29, 1354–

559 1364 (2019).

560 16. Lee, S. H. & Wray, N. R. Novel Genetic Analysis for Case-Control Genome-Wide Association

561 Studies: Quantification of Power and Genomic Prediction Accuracy. *PLoS ONE* **8**, (2013).

- 562 17. Dasaro, C. R. *et al.* Cohort Profile: World Trade Center Health Program General Responder
- 563 Cohort. *Int. J. Epidemiol.* **46**, e9 (2017).
- 18. Ruggiero, K. J., Del Ben, K., Scotti, J. R. & Rabalais, A. E. Psychometric properties of the PTSD
- 565 Checklist-Civilian Version. J. Trauma. Stress 16, 495–502 (2003).

- 566 19. Huckins, L. M. *et al.* Polygenic regulation of PTSD severity and outcomes among World
- 567 Trade Center responders. *medRxiv* 2020.12.06.20244772 (2020)
- 568 doi:10.1101/2020.12.06.20244772.
- 569 20. Bernstein, D. P. et al. Development and validation of a brief screening version of the
- 570 Childhood Trauma Questionnaire. *Child Abuse Negl.* **27**, 169–190 (2003).
- 571 21. Kubany, E. S. *et al.* Development and preliminary validation of a brief broad-spectrum
- 572 measure of trauma exposure: the Traumatic Life Events Questionnaire. *Psychol. Assess.* 12,
- 573 210–224 (2000).
- 574 22. North, CS., et al. The Diagnostic Interview Schedule/Disaster Supplement (DIS-IV/DS). St
- 575 *Louis Wash. Univ.* (2001).
- 576 23. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Medical comorbidity of full
- and partial posttraumatic stress disorder in US adults: results from Wave 2 of the National
- 578 Epidemiologic Survey on Alcohol and Related Conditions. *Psychosom. Med.* 73, 697–707
- 579 (2011).
- 580 24. Horn, S. R. *et al.* Latent typologies of posttraumatic stress disorder in World Trade Center
  581 responders. *J. Psychiatr. Res.* 83, 151–159 (2016).
- 582 25. Pietrzak, R. H., Tsai, J., Harpaz-Rotem, I., Whealin, J. M. & Southwick, S. M. Support for a
- 583 novel five-factor model of posttraumatic stress symptoms in three independent samples of
- 584 Iraq/Afghanistan veterans: a confirmatory factor analytic study. J. Psychiatr. Res. 46, 317–
- 585 322 (2012).
- 586 26. Shah, H., Wang, Y.-C., Castellanos, R., Pandya, C., & Giles, Z. RAPiD An Agile and
- 587 Dependable RNA-Seq Framework. *ASHG 2015* (2015).

- 588 27. Hoffman, G. E. & Schadt, E. E. variancePartition: interpreting drivers of variation in complex
  589 gene expression studies. *BMC Bioinformatics* 17, 483 (2016).
- 590 28. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model
- analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014).
- 592 29. Mellon, S. H., Gautam, A., Hammamieh, R., Jett, M. & Wolkowitz, O. M. Metabolism,
- 593 Metabolomics, and Inflammation in Posttraumatic Stress Disorder. *Biol. Psychiatry* 83, 866–
- 594
   875 (2018).
- 595 30. Wisnivesky, J. P. *et al.* Persistence of multiple illnesses in World Trade Center rescue and
- 596 recovery workers: a cohort study. *Lancet Lond. Engl.* **378**, 888–897 (2011).
- 597 31. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful
  598 Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
- 599 32. Bild, A. & Febbo, P. G. Application of a priori established gene sets to discover biologically
- 600 important differential expression in microarray data. Proc. Natl. Acad. Sci. 102, 15278–
- 601 15279 (2005).
- 602 33. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. *bioRxiv*603 060012 (2019) doi:10.1101/060012.
- 604 34. How to do GSEA in R with (fgsea or gage) and plot results. *Bioinformatics Breakdown*
- 605 https://bioinformaticsbreakdown.com/how-to-gsea/ (2019).
- 606 35. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference
- 607 resource for gene and protein annotation. *Nucleic Acids Res.* 44, D457–D462 (2016).
- 608 36. Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R Package for Comparing
- Biological Themes Among Gene Clusters. *OMICS J. Integr. Biol.* **16**, 284–287 (2012).

- 610 37. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
- 611 association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 612 38. Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles.
- 613 *Nat. Methods* **12**, 453–457 (2015).
- 614 39. Daskalakis, N. P., Rijal, C. M., King, C., Huckins, L. M. & Ressler, K. J. Recent Genetics and
- 615 Epigenetics Approaches to PTSD. *Curr. Psychiatry Rep.* **20**, 30 (2018).
- 40. Neigh, G. N. & Ali, F. F. Co-Morbidity of PTSD and Immune System Dysfunction:
- 617 Opportunities for Treatment. *Curr. Opin. Pharmacol.* **29**, 104–110 (2016).
- 618 41. Wang, Z., Caughron, B. & Young, M. R. I. Posttraumatic Stress Disorder: An Immunological
- 619 Disorder? Front. Psychiatry 8, (2017).
- 42. Speer, K. E., Semple, S., Naumovski, N., D'Cunha, N. M. & McKune, A. J. HPA axis function
- 621 and diurnal cortisol in post-traumatic stress disorder: A systematic review. *Neurobiol. Stress*
- 622 **11**, (2019).
- 623 43. Yehuda, R. et al. Post-traumatic stress disorder. Nat. Rev. Dis. Primer 1, 1–22 (2015).
- 624 44. Nutt, D. J. & Malizia, A. L. Structural and functional brain changes in posttraumatic stress
- 625 disorder. J. Clin. Psychiatry 65 Suppl 1, 11–17 (2004).
- 45. Duncan, L. E. *et al.* Largest GWAS of PTSD (N=202070) yields genetic overlap with
- 627 schizophrenia and sex differences in heritability. *Mol. Psychiatry* **23**, 666–673 (2018).
- 628 46. Li, Z. et al. Genome-wide association analysis identifies 30 new susceptibility loci for
- 629 schizophrenia. *Nat. Genet.* **49**, 1576–1583 (2017).
- 630 47. Jong, S. de *et al.* Immune signatures and disorder-specific patterns in a cross-disorder gene
- 631 expression analysis. *Br. J. Psychiatry* **209**, 202–208 (2016).

- 632 48. Tsolakidou, A. *et al.* Gene expression profiling in the stress control brain region
- 633 hypothalamic paraventricular nucleus reveals a novel gene network including Amyloid beta
- 634 Precursor Protein. *BMC Genomics* **11**, 546 (2010).
- 635 49. Maccarrone, G. et al. Psychiatric patient stratification using biosignatures based on
- 636 cerebrospinal fluid protein expression clusters. J. Psychiatr. Res. 47, 1572–1580 (2013).
- 637 50. Hou, Y. et al. Schizophrenia-associated rs4702 G allele-specific downregulation of FURIN
- 638 expression by miR-338-3p reduces BDNF production. *Schizophr. Res.* **199**, 176–180 (2018).
- 639 51. Schrode, N. et al. Synergistic effects of common schizophrenia risk variants. Nat. Genet. 51,
- 640 1475–1485 (2019).
- 52. English, J. A. *et al.* Reduced protein synthesis in schizophrenia patient-derived olfactory
- 642 cells. *Transl. Psychiatry* **5**, e663–e663 (2015).
- 53. Miron, J. *et al.* Association of PPP2R1A with Alzheimer's disease and specific cognitive
- 644 domains. *Neurobiol. Aging* **81**, 234–243 (2019).
- 645 54. Bralten, J. *et al.* Candidate Genetic Pathways for Attention-Deficit/Hyperactivity Disorder
- 646 (ADHD) Show Association to Hyperactive/Impulsive Symptoms in Children With ADHD. J.
- 647 Am. Acad. Child Adolesc. Psychiatry **52**, 1204-1212.e1 (2013).
- 55. Chang, W.-S., Wang, Y.-H., Zhu, X.-T. & Wu, C.-J. Genome-Wide Profiling of miRNA and
- 649 mRNA Expression in Alzheimer's Disease. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* 23,
- 650 2721–2731 (2017).
- 651 56. Kawai, T. *et al.* Gene expression signature in peripheral blood cells from medical students
- exposed to chronic psychological stress. *Biol. Psychol.* **76**, 147–155 (2007).

- 653 57. Zhao, Y. *et al.* A large-scale integrative analysis of GWAS and common meQTLs across whole
- 654 life course identifies genes, pathways and tissue/cell types for three major psychiatric
- 655 disorders. *Neurosci. Biobehav. Rev.* **95**, 347–352 (2018).
- 556 58. Konno, T. *et al.* DCTN1-related neurodegeneration: Perry syndrome and beyond.
- 657 *Parkinsonism Relat. Disord.* **41**, 14–24 (2017).
- 59. Seth, A., Giunta, S., Franceschil, C., Kola, I. & Venanzoni, M. C. Regulation of the human
- 659 stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products. *Cell Death*
- 660 *Differ.* **6**, 902–907 (1999).
- 661 60. St-Louis, É. *et al.* Involvement of the coatomer protein complex I in the intracellular traffic
- of the delta opioid receptor. *Mol. Cell. Neurosci.* **79**, 53–63 (2017).
- 663 61. Bettayeb, K. *et al.* Relevance of the COPI complex for Alzheimer's disease progression in
- 664 vivo. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 5418–5423 (2016).
- 665 62. Yang, Y., Wang, X., Ju, W., Sun, L. & Zhang, H. Genetic and Expression Analysis of COPI
- 666 Genes and Alzheimer's Disease Susceptibility. *Front. Genet.* **10**, 866 (2019).
- 667 63. Izumi, K. et al. ARCN1 Mutations Cause a Recognizable Craniofacial Syndrome Due to COPI-
- 668 Mediated Transport Defects. Am. J. Hum. Genet. **99**, 451–459 (2016).
- 669 64. Watkin, L. B. *et al.* COPA mutations impair ER-Golgi transport and cause hereditary
- autoimmune-mediated lung disease and arthritis. *Nat. Genet.* **47**, 654–660 (2015).
- 671 65. Jean, F., Stuart, A. & Tarailo-Graovac, M. Dissecting the Genetic and Etiological Causes of
- 672 Primary Microcephaly. *Front. Neurol.* **11**, (2020).

- 673 66. Lippmann, M., Cohen, M. D. & Chen, L.-C. Health effects of World Trade Center (WTC) Dust:
- 674 An unprecedented disaster with inadequate risk management. *Crit. Rev. Toxicol.* 45, 492–
- 675 530 (2015).
- 676 67. Reibman, J. *et al.* Characteristics of a Residential and Working Community With Diverse
- 677 Exposure to World Trade Center Dust, Gas, and Fumes. J. Occup. Environ. Med. Am. Coll.
- 678 *Occup. Environ. Med.* **51**, 534–541 (2009).
- 679 68. Hervé, M. et al. Translational Identification of Transcriptional Signatures of Major
- 680 Depression and Antidepressant Response. *Front. Mol. Neurosci.* **10**, (2017).
- 681 69. Carlini, V. et al. CLIC1 Protein Accumulates in Circulating Monocyte Membrane during
- 682 Neurodegeneration. Int. J. Mol. Sci. 21, (2020).
- 683 70. Tang, T. *et al.* CLICs-dependent chloride efflux is an essential and proximal upstream event
- 684 for NLRP3 inflammasome activation. *Nat. Commun.* **8**, 202 (2017).
- 685 71. Gurunathan, G., Yu, Z., Coulombe, Y., Masson, J.-Y. & Richard, S. Arginine methylation of
- 686 hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage. *Sci.*
- 687 *Rep.* **5**, 10475 (2015).
- 688 72. Baker, K. *et al.* Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG
- 689 immune complexes by CD8–CD11b+ dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 108, 9927–
- 6909932 (2011).
- 691 73. Le-Niculescu, H. et al. Towards precision medicine for stress disorders: diagnostic
- biomarkers and targeted drugs. *Mol. Psychiatry* **25**, 918–938 (2020).
- 693 74. Zhu, X., Bührer, C. & Wellmann, S. Cold-inducible proteins CIRP and RBM3, a unique couple
- 694 with activities far beyond the cold. *Cell. Mol. Life Sci.* **73**, 3839–3859 (2016).

- 75. Zhou, J.-Y. *et al.* Trauma-associated Human Neutrophil Alterations Revealed by Comparative
  Proteomics Profiling. *Proteomics Clin. Appl.* 7, (2013).
- 697 76. Lu, Q., Shen, N., Li, X. M. & Chen, S. L. Genomic view of IFN-α response in pre-autoimmune
- 698 NZB/W and MRL/lpr mice. *Genes Immun.* **8**, 590–603 (2007).
- 699 77. Chen, Y., Li, X., Kobayashi, I., Tsao, D. & Mellman, T. A. Expression and methylation in
- 700 posttraumatic stress disorder and resilience; evidence of a role for odorant receptors.
- 701 *Psychiatry Res.* **245**, 36–44 (2016).
- 702 78. Breen, M. S. *et al.* Differential transcriptional response following glucocorticoid activation in
- cultured blood immune cells: a novel approach to PTSD biomarker development. *Transl.*
- 704 *Psychiatry* **9**, 201 (2019).
- 705 79. Glover, D. A., Steele, A. C., Stuber, M. L. & Fahey, J. L. Preliminary evidence for lymphocyte
- distribution differences at rest and after acute psychological stress in PTSD-symptomatic
- 707 women. Brain. Behav. Immun. **19**, 243–251 (2005).
- 80. Lemieux, A., Coe, C. L. & Carnes, M. Symptom severity predicts degree of T cell activation in
- adult women following childhood maltreatment. *Brain. Behav. Immun.* 22, 994–1003
- 710 (2008).
- 81. Skapenko, A., Leipe, J., Lipsky, P. E. & Schulze-Koops, H. The role of the T cell in autoimmune
  inflammation. *Arthritis Res. Ther.* 7, S4–S14 (2005).
- 713 82. Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M. & Mondelli, V. Childhood trauma and
- adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and
- tumour necrosis factor-α. *Mol. Psychiatry* **21**, 642–649 (2016).

- 716 83. Dong, Y. et al. Stress-induced NLRP3 inflammasome activation negatively regulates fear
- 717 memory in mice. J. Neuroinflammation **17**, 205 (2020).
- 718 84. Fonkoue, I. T. *et al.* Symptom severity impacts sympathetic dysregulation and inflammation
- in post-traumatic stress disorder (PTSD). *Brain. Behav. Immun.* **83**, 260–269 (2020).
- 720 85. Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J. & Jovanovic, T. Inflammation in
- 721 Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond. *Neuropsychopharmacology* **42**,
- 722 254–270 (2017).
- 723 86. Speer, K., Upton, D., Semple, S. & McKune, A. Systemic low-grade inflammation in post-
- traumatic stress disorder: a systematic review. J. Inflamm. Res. **11**, 111–121 (2018).

725





Β.

A. Total Lifetime CAPS Score



# Total Past-month CAPS Score



C. Lifetime Anxious Arousal



# D. Past-month Anxious Arousal











Long-term potentiation Renin secretion Gastric acid secretion

> Pertussis Gap junction

> > Total CAPS

Anxious Arousal

Numbing

Α.



